FI115051B - Nytt amidinonaftylderivat eller dess salt - Google Patents

Nytt amidinonaftylderivat eller dess salt Download PDF

Info

Publication number
FI115051B
FI115051B FI972326A FI972326A FI115051B FI 115051 B FI115051 B FI 115051B FI 972326 A FI972326 A FI 972326A FI 972326 A FI972326 A FI 972326A FI 115051 B FI115051 B FI 115051B
Authority
FI
Finland
Prior art keywords
group
methyl
oxy
piperidyl
phenyl
Prior art date
Application number
FI972326A
Other languages
English (en)
Finnish (fi)
Other versions
FI972326A (sv
FI972326A0 (sv
Inventor
Yuzo Matsumoto
Isao Yanagisawa
Hiroyuki Koshio
Fukushi Hirayama
Tomihisa Kawasaki
Seiji Kaku
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of FI972326A publication Critical patent/FI972326A/sv
Publication of FI972326A0 publication Critical patent/FI972326A0/sv
Application granted granted Critical
Publication of FI115051B publication Critical patent/FI115051B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (11)

1. Amidinonaftylderivat med följande allmänna formel (I) HN _ R1 , HN R2
1 I » » * ♦ » - t 115051 112
2. Amidinonaftylderivat enligt patentkravet 1 eller dess farmaceutiskt godtagbara salt, kän- netecknat därav, att R4 är hydroxyl; Q-Q-alkoxi; CrQ-alkyl, som kan vara substituerad med en eller flera substituenter ur gruppen halogen, karboxyl, karbamoyl, amino, Ci-C6-alkoxi, (Ci-C6-alkoxi)karbonyl, mono- eller di- CrQ-alkylamino och fenyl; cykloalkyl; aryl, som kan vara substituerad med en eller flera substituenter ur gruppen halogen, amino, nitro, 10 karboxyl, (Ci-C6-alkoxi)karbonyl och Ci-C6-alkoxi; eller heteroaryl; förutsatt att dl W är en grupp med formel -NR5-, R4 kan därtill avse väte, men inte hydroxyl eller CrQ-alkoxi, R5 är väte; karbamoyl; (Cj-C6-alkoxi)karbonyl; CrQ-alkanoyl eller mono- eller di-Ci-Ce-alkyl-aminotiokarbonyl; eller Ci-C6-alkyl, och 15 R3 är väte, halogen, karboxyl, Cj-Q-alkoxi, Q-Q-alkylgrupp eller (Ci-C6*alkoxi)karbonyl.
3. Amidinonaftylderivat enligt patentkravet 2 eller dess farmaceutiskt godtagbara salt, kän-netecknat därav, att gruppen med formeln -A-W-R4 är Ci-C6-alkanoyl, som kan vara substi-20 tuerad med Ci-C6-alkoxi, Ci-C6-alkoxikarbonyl eller mono- eller di- Ci-Qralkylamino; amino-karbonyl, som kan vara substituerad med (Ci-C6-alkoxi)karbonyl; Ci-C6-alkylsulfonyl, som * kan vara substituerad med halogen, karboxyl, karbamoyl, (Cj-C6-alkoxi)karbonyl eller fenyl; : mono- och di-(Ci-C6-alkyl)aminokarbonyl, som kan vara substituerad med karboxyl eller (Ci-C6-alkoxi)karbonyl; aminosulfonyl, som kan vara substituerad med (Ci-C6-alkoxi)karbon- * : 25 yl; mono- och di-CrC6-alkylaminosulfonyl, som kan vara substituerad med karbamoyl, kar- " boxyl eller (Ci-C6-alkoxi)karbonyl; N-(Ci-C6-alkyl)-N-(Ci-C6-alkoxi)karbonylaminosulfonyl, som > kan vara substituerad med karboxyl eller (CrC6-alkoxi)karbonyl; bensoyl, som kan vara substituerad med karboxyl, CrC6-alkoxi, (Ci-C6-alkoxi)karbonyl eller halogen, bensensulfonyl, • som kan vara substituerad med amino, nitro, karboxyl eller (Ci-C5-alkoxi)karbonyl; naftoyl; *’ 30 mono-(Ci-Q-alkyl)aminotiokarbonyl; pyridylkarbonyl; tienylkarbonyl; amino-oxalyl och cyklo- • alkylkarbonyl, och R3 är väte eller Ci-Q-alkoxikarbonyl. 1
* : 4. Amidinonaftylderivat enligt patentkravet 1 eller 3 eller dess farmaceutiskt godtagbara salt, : kännetecknat därav, att A är en grupp med formeln 35 115051 114 O O Il II -c- c-
5. Amidinonaftylderivat enligt patentkravet 1 eller 2 farmaceutiskt godtagbara sait, känne- tecknat därav, att A är en grupp med formeln -S02-.
5 Y'OO'-- YtrJ Y ,.. (CH2i dar R1: en väteatom eller en grupp med formel -A-W-R4,
6. Amidinonaftylderivat enligt patentkravet 1, som är vald ur gruppen N-[4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl-N'-metylsulfamid, etyl-N-[N-4-[(l-aceto- 10 imidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]sulfamoyl]karbamat, 4-[N-4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]sulfamoyl]bensoesyra, [N-[4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]sulfamoyl]ättiksyra, etyl-N-[N-[4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]sulfamoyl]-glycinat, N-[N-4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]-15 sulfamoyl]-N-etoxikarbonylglycin eller N-[N-4-[(l-acetoimidoyl-4-piperidyl)oxi]fenyl]-N-[(7-amidino-2-naftyl)metyl]sulfamoyl]glycin eller dess farmaceutiskt godtagbara sait.
7. Mellanprodukt med följande allmänna formel (10 » "vm j' >· , : (CH2)n ; ’ där R1, B, R3 och n är definierade i vilket som heist av kraven 1-5. ’ ' 25 t t * > I ;_
8. Farmaceutisk blandning, kännetecknad därav, att den innehäller en farmaceutiskt god- » k ) * ·; ·, tagbar förening enligt vilken som heist av patentkraven 1-6.
9. Farmaceutisk blandning enligt patentkravet 8, kännetecknad därav, att den utgörs av en , 30 inhibitor till koagulationsfaktor X för aktiverat blod. »
10. Farmaceutisk blandning enligt patentkravet 8, kännetecknad därav, att den utgörs av . » en inhibitor för blodkoagulationsfaktorn. » k 115051 115
10 X 0 0 II II II A: en grupp med formeln -C-, formeln -C- C eller formeln -S02-, X: en syreatom eller svavelatom, W: en enkel bindning eller en grupp med formel -NR5-,
15 R4: hydroxyl; Ci-C6-alkoxi; CrC6-alkyl, som kan vara substituerad med en eller flera substitu- enter C ur gruppen: halogen, karboxyl, karbamoyl, amino, cyan, nitro, hydroxyl, Ci-C6-alkanoyl, Ci-C6-alkoxi, (Ci-C6-alkoxi)karbonyl, mono- och di- Ci-Q-alkylamino och Q-Cw-aryl; C3-C8-cykloalkyl; C6-Ci4-aryl, som kan vara substituerad med en eller flera substituenter D ur gruppen: halogen, karboxyl, amino, cyan, nitro, hydroxyl, CrC6-alkoxi, (CrQ-alkoxOkarbon-20 yl, mono eller di- CrQ-alkylamino, Ci-Q-alkanoyl och Ci-Q-alkyl, som kan vara substituerad med en eller flera av gruppens C grupper; eller en heteroarylgrupp ur gruppen furyl, tienyl, pyrrolyl, imidazolyl, pyrazolyl, isotiazolyl, isoxazolyl, pyridyl, pyrimidnyl, kinolyl, isokinolyl, « t * kinazolinyl, kinolizinyl, kinoxalinyl, kinolinyl; bensimidazolyl, imidazopyridyl, bensofuranyl, naftryridnyl, 1,2-bensoisoxazolyl, bensoxazolyl, bensotiazolyl, oxazolopyridyl, isotiazolopyridyl I·,*: 25 och bensotienyl, förutsatt, att dä W är en grupp med formeln -NR5-, R4 kan därtill avse en väteatom men inte . ·, hydroxyl eller CrQ-alkoxi, R5: väte, karbamoyl, Cx-Q-alkoxikarbonyl, mono eller di-Ci-Q-alkylaminokarbonyl, Ci-C6-alkylsulfonyl, mono- eller di-(Ci-C6-alkyl)aminotiokarbonyl, CrQ-alkyl eller Ci-Q-alkanoyl,
30 R2: CrQ-alkyl, » R3: väte, halogen, karboxyl, amino, cyan, nitro, hydroxyl, Ci-C6-alkoxi, en Ci-Q-alkylgrupp '; eller (Ci-C6-alkoxi)karbonyl, * · B: CrQ-alkylen eller karbonyl, och : n: 0 eller 1, 113 115051 eller dess tautomerer och geometriska och optiska isomerer, dessa derivats, tautomerers och isomerers salt och dessa derivats, tautomerers, isomerers och salters hydrater och farmaceu-tiskt godtagbara soivat.
11. Användningen av en farmaceutisk blandning enligt nägot av patentkraven 1 - 6 för fram-ställning av ett läkemedel för profylax och värd av en sjukdom förorsakad av trombos eller blodpropp. « * * l » I i » 1*1 t < * « ♦ * » • · • t • · > » 1 • · t I * 1. t > ·
FI972326A 1994-12-02 1997-06-02 Nytt amidinonaftylderivat eller dess salt FI115051B (sv)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP29996394 1994-12-02
JP29996394 1994-12-02
JP10520595 1995-04-28
JP10520595 1995-04-28
JP19881695 1995-08-03
JP19881695 1995-08-03
JP9502458 1995-12-01
PCT/JP1995/002458 WO1996016940A1 (fr) 1994-12-02 1995-12-01 Nouveau derive d'amidinonaphtyle ou sel de celui-ci

Publications (3)

Publication Number Publication Date
FI972326A FI972326A (sv) 1997-06-02
FI972326A0 FI972326A0 (sv) 1997-06-02
FI115051B true FI115051B (sv) 2005-02-28

Family

ID=27310425

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972326A FI115051B (sv) 1994-12-02 1997-06-02 Nytt amidinonaftylderivat eller dess salt

Country Status (20)

Country Link
US (1) US5869501A (sv)
EP (1) EP0798295B1 (sv)
JP (1) JP3004362B2 (sv)
KR (1) KR100383161B1 (sv)
CN (1) CN1087736C (sv)
AT (1) ATE233240T1 (sv)
AU (1) AU688628B2 (sv)
CA (1) CA2206532C (sv)
DE (1) DE69529770T2 (sv)
ES (1) ES2193202T3 (sv)
FI (1) FI115051B (sv)
HU (1) HUT77313A (sv)
MX (1) MX9704059A (sv)
NO (1) NO309566B1 (sv)
NZ (1) NZ296210A (sv)
PL (1) PL184824B1 (sv)
PT (1) PT798295E (sv)
RU (1) RU2154633C2 (sv)
TW (1) TW300888B (sv)
WO (1) WO1996016940A1 (sv)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
EP0842941A1 (de) 1996-11-16 1998-05-20 Roche Diagnostics GmbH Neue Phosphonate, Verfahren zu ihrer Herstellung und Arzneimittel
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
AU7976998A (en) * 1997-06-19 1999-01-04 Du Pont Merck Pharmaceutical Company, The (amidino)6-membered aromatics as factor xa inhibitors
ZA986594B (en) * 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
WO1999011617A1 (fr) * 1997-09-01 1999-03-11 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de naphtamide et sels de ces derives
US6686364B2 (en) 1997-12-08 2004-02-03 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
DE19754490A1 (de) * 1997-12-09 1999-06-10 Boehringer Ingelheim Pharma Durch einen Aminocarbonylrest substituierte Bicyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
AU1692399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0937723A1 (de) * 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP1066272A4 (en) * 1998-03-27 2002-03-13 Biocryst Pharm Inc NEW CONNECTIONS USEFUL IN THE COMPLEMENT, COAGULATE AND KALLIKREIN REACTION WAY AND METHOD FOR THEIR PRODUCTION
SK15072000A3 (sk) 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
US6504031B1 (en) 1998-08-06 2003-01-07 Milan Bruncko Naphthamidine urokinase inhibitors
US6284796B1 (en) 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
CA2320730A1 (en) 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
ATE307111T1 (de) 1999-01-13 2005-11-15 Genentech Inc Serinprotease-inhibitoren
JP4599714B2 (ja) * 1999-01-22 2010-12-15 アステラス製薬株式会社 経口吸収改善医薬用組成物
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
FR2793247B1 (fr) * 1999-05-04 2001-06-22 Synthelabo Derives de 6-[[(aryl et heteroaryl)oxy]methyl]naphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
WO2001002356A1 (fr) * 1999-07-01 2001-01-11 Sankyo Company, Limited Dérivés d'indoline ou tétrahydroquinoline
US6350761B1 (en) * 1999-07-30 2002-02-26 Berlex Laboratories, Inc. Benzenamine derivatives as anti-coagulants
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU776193B2 (en) 1999-10-28 2004-09-02 Sankyo Company Limited Benzamidine derivatives
EP1095933A1 (en) * 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
WO2001056989A2 (en) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US6548517B2 (en) * 2000-03-24 2003-04-15 Millennium Pharmaceuticals, Inc. Oxindole inhibitors of factor Xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6495562B1 (en) 2000-04-25 2002-12-17 Abbott Laboratories Naphthamidine urokinase inhibitors
US6410733B1 (en) 2000-09-11 2002-06-25 Genentech, Inc. Amidine inhibitors of serine proteases
CA2424522C (en) * 2000-11-22 2009-12-29 Yamanouchi Pharmaceutical Co., Ltd. Substituted benzene derivatives or salts thereof
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
JP2004520438A (ja) 2001-03-09 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド セリンプロテアーゼインヒビターとしてのアミノピロリジンスルホンアミド
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
AU2002246336B2 (en) 2001-04-05 2005-05-19 Sankyo Company, Limited Benzamidine derivative
SI1470102T1 (sl) * 2002-01-29 2011-08-31 Merck Serono Sa Substituirani derivati metilen amida kot modulatorji proteinskih tirozinskih fosfataz (ptp)
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
US7479502B2 (en) 2002-12-03 2009-01-20 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
WO2004058728A1 (ja) * 2002-12-24 2004-07-15 Daiichi Pharmaceutical Co., Ltd. 新規なエチレンジアミン誘導体
WO2004113316A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
EP1628954A2 (en) 2003-05-20 2006-03-01 Genentech, Inc. Acylsulfamide inhibitors of factor viia
EP1678161B1 (en) 2003-10-09 2009-12-30 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1893572B1 (en) 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7612089B2 (en) 2004-11-19 2009-11-03 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor Xa inhibitors
US20060160790A1 (en) * 2004-12-07 2006-07-20 Portola Pharmaceuticals, Inc. Thioureas as factor Xa inhibitors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2006083003A1 (ja) 2005-02-02 2006-08-10 Ajinomoto Co., Inc. 新規ベンズアミジン化合物
JP5227178B2 (ja) 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
CA2644369A1 (en) * 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
AU2007307599A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. N-phenyloxamic acid derivatives
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
JPWO2008066102A1 (ja) * 2006-11-30 2010-03-11 武田薬品工業株式会社 徐放性製剤
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2311810A4 (en) * 2008-07-11 2012-04-04 Ajinomoto Kk AMIDINE DERIVATIVE
EA015918B1 (ru) 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
US11679093B2 (en) 2018-06-11 2023-06-20 The Regents Of The University Of Colorado, A Body Corporate 2-naphthimidamides, analogues thereof, and methods of treatment using same
CN117304076B (zh) * 2023-11-28 2024-02-20 苏州大学 一种n-磺酰基脒化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) * 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
US4563527A (en) * 1984-07-19 1986-01-07 Torii & Co., Ltd. Amidine compounds
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.

Also Published As

Publication number Publication date
EP0798295A4 (en) 1998-03-04
FI972326A (sv) 1997-06-02
DE69529770T2 (de) 2003-12-24
NO309566B1 (no) 2001-02-19
JP3004362B2 (ja) 2000-01-31
HUT77313A (hu) 1998-03-30
PL320486A1 (en) 1997-09-29
AU688628B2 (en) 1998-03-12
PL184824B1 (pl) 2002-12-31
CA2206532C (en) 2006-07-11
DE69529770D1 (de) 2003-04-03
FI972326A0 (sv) 1997-06-02
EP0798295A1 (en) 1997-10-01
PT798295E (pt) 2003-07-31
CN1167484A (zh) 1997-12-10
AU3994295A (en) 1996-06-19
NO972482D0 (no) 1997-05-30
WO1996016940A1 (fr) 1996-06-06
MX9704059A (es) 1997-08-30
ES2193202T3 (es) 2003-11-01
US5869501A (en) 1999-02-09
TW300888B (sv) 1997-03-21
CN1087736C (zh) 2002-07-17
NO972482L (no) 1997-08-01
RU2154633C2 (ru) 2000-08-20
CA2206532A1 (en) 1996-06-06
KR100383161B1 (ko) 2003-12-24
NZ296210A (en) 1998-05-27
ATE233240T1 (de) 2003-03-15
EP0798295B1 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
FI115051B (sv) Nytt amidinonaftylderivat eller dess salt
EP3328843B1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR100637110B1 (ko) 세포 유착 억제제
RU2361861C2 (ru) Производное циклического амида, его получение и применение
EP2876105A1 (en) 1-(cycloalkyl-carbonyl)proline derivative
US9920034B2 (en) Crystalline forms of a factor XIa inhibitor
KR100739359B1 (ko) 디아제판 유도체 또는 이의 염
TW202332674A (zh) Tlr7/8拮抗劑及其用途
EP1695961A1 (en) Urea derivative, process for producing the same, and use
WO2002006234A1 (fr) Derives de sulfonate, procede de production et utilisation de ces derives
EP1950199A1 (en) Proline derivatives and use thereof as drugs
WO2004048363A1 (ja) イミダゾール誘導体、その製造法および用途
EP0562599A1 (en) Condensed thiadiazole derivative, method of its production, and use thereof
AU759488B2 (en) Amino acid derivatives and drugs containing the same as the active ingredient
EP2138482A1 (en) Bicyclic heterocyclic compound
JPH02290841A (ja) 新規化合物、その製法及びそれを含む医薬組成物
KR20050121681A (ko) 면역조절 헤테로고리 화합물
CA3196061A1 (en) Cftr modulator compounds, compositions, and uses thereof
EP1852431A1 (en) Optically active tetrahydronaphthalene derivative
JP4250423B2 (ja) アリール置換脂環式化合物及びそれを含有する医薬組成物
WO2007055183A1 (ja) ベンゼン誘導体又はその塩
WO1997002245A1 (fr) Derives de benzamidoxime et leur utilisation a des fins medicinales
JPH04128291A (ja) 新規なヘテロ環化合物およびその製造法
JP2842302B2 (ja) チアゾリン誘導体
JP4214524B2 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115051

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: ASTELLAS PHARMA INC.

Free format text: ASTELLAS PHARMA INC.

MA Patent expired